Related Experiment Video

Updated: Dec 30, 2025

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.4K

Safety and immunogenicity of vesicular stomatitis virus-based vaccines for Ebola virus disease

Marc-Antoine de La Vega1, Gary P Kobinger2

  • 1Département de microbiologie-infectiologie et immunologie, Université Laval, Quebec, QC G1V 4G2, Canada.

The Lancet. Infectious Diseases
|January 19, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

36.9K
Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

59.6K

Related Experiment Videos

Last Updated: Dec 30, 2025

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.4K
Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

36.9K
Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

59.6K

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

32.7K
Overview
32.7K

Articles linked to this work by shared authors, journal, and citation graph.

An engineered intradermal microneedle-array device enhances the cellular immune responses in a guinea pig model.

Frontiers in immunology·2026

A phase Ib, placebo-controlled randomized clinical trial of the Ebolavirus DNA vaccine candidate INO-4201 followed by electroporation as booster vaccination in healthy, rVSVΔG-ZEBOV-GP-primed volunteers (Boost-EBOV).

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026

Zika Virus Reprograms Microglial Mitochondrial Metabolism to Support Immune Activation and Viral Replication: Omega-3 DHA Counteracts Neuroinflammation and Viral Persistence.

Molecular neurobiology·2026

Mpox animal models: a comprehensive evaluation of susceptible species for pathogenesis studies and drug discovery.

Emerging microbes & infections·2025

Global health at crossroads: uniting together to overcome challenges, restore trust and advance priorities for a sustainable future.

World journal of emergency surgery : WJES·2025

Field Evaluation of Mobile Molecular Differential Tests in DRC and Nigeria.

Open forum infectious diseases·2025

Second-season observations after prophylaxis in the evaluation of the impact of nirsevimab in Galicia (NIRSE-GAL) study: mechanistic interpretation and implications for respiratory syncytial virus prevention strategy.

The Lancet. Infectious diseases·2026

Daptomycin for enterococcal bloodstream infections and endocarditis: reconciling clinical evidence, susceptibility testing, and regulatory frameworks.

The Lancet. Infectious diseases·2026

Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace).

The Lancet. Infectious diseases·2026

When the fungus is susceptible, but the patient is not: reading antifungal susceptibility from bench to bedside.

The Lancet. Infectious diseases·2026

Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study.

The Lancet. Infectious diseases·2026

Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, evaluated with and without tetanus-reduced diphtheria-acellular pertussis vaccine in healthy children aged 6-17 years: a randomised, active-controlled and placebo-controlled, phase 2b trial.

The Lancet. Infectious diseases·2026

Sex and age distribution of schizophrenia admissions at a psychiatric hospital in Morocco (2011-2024).

Dialogues in health·2026

Vortioxetine-Associated Rapid Eye Movement (REM) Sleep Alterations: A Focused Narrative Review of Human Polysomnographic Evidence.

Cureus·2026

Nonlinear association of early serum albumin with 28-day ICU mortality in adults with an admission diagnosis of sepsis: a multicenter eICU cohort study.

Frontiers in medicine·2026

Study on the operational efficiency of clinical departments in a Grade III general hospital.

Frontiers in public health·2026

Early hematoma expansion provides incremental prognostic information beyond admission characteristics for 6-month functional outcome after adult traumatic brain injury.

Frontiers in neurology·2026

Multimodal digital assessment of early recovery after chest tube omission in early-stage lung cancer patients undergoing wedge resection: a post hoc analysis of a prospective cohort.

Translational lung cancer research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us